$40.99 / month – $384.99
Ara-290 10 ML is a high-purity research peptide classified under anti-inflammatory, neuroprotective, and recovery applications. This laboratory-grade peptide meets stringent quality standards, ensuring optimal performance in research settings. It has been investigated in studies for its potential in metabolic and neuroprotective research. For laboratory research use only. Not for human consumption.
Ara 290 peptide benefits represent a breakthrough in neuroprotective and tissue-protective therapeutics. This innovative 11-amino acid peptide, also known as cibinetide, derives from the three-dimensional structure of erythropoietin’s helix B domain, specifically engineered to retain tissue-protective properties while eliminating erythropoietic activity. The ara 290 peptide benefits occur through selective activation of the innate repair receptor (IRR), a heterodimer consisting of the erythropoietin receptor and CD131 (β-common receptor). This unique mechanism allows ara 290 peptide to promote tissue protection, reduce inflammation, and stimulate nerve regeneration without the cardiovascular risks associated with traditional erythropoietin therapy.
PrymaLab’s Ara-290 10ML formulation provides pharmaceutical-grade peptide suitable for extended research protocols investigating neuroprotection and tissue repair. The ara 290 peptide benefits extend across multiple physiological systems, with particular efficacy demonstrated in treating diabetic neuropathy, chronic neuropathic pain, and inflammatory conditions. Clinical trials have established that ara 290 peptide benefits include improved nerve fiber density, reduced neuropathic symptoms, enhanced metabolic control, and superior lipid profiles. The 10ML volume offers sufficient capacity for comprehensive research cycles while maintaining optimal peptide stability and potency throughout the treatment period.
The molecular structure of ara 290 peptide enables it to interact selectively with the innate repair receptor without binding to the classical erythropoietin receptor homodimer responsible for red blood cell production. This selectivity represents a critical advantage, as ara 290 peptide benefits include all the tissue-protective effects of erythropoietin without the serious side effects of increased hematocrit, thrombosis risk, and cardiovascular complications. Researchers can confidently investigate ara 290 peptide benefits for neuroprotection, knowing the compound maintains an excellent safety profile established through multiple clinical trials and preclinical studies.
The ara 290 peptide benefits originate from its sophisticated interaction with the innate repair receptor, a specialized signaling complex that mediates tissue protection and repair responses. When ara 290 peptide binds to the IRR, it initiates a cascade of intracellular signaling pathways that promote cell survival, reduce inflammation, and activate healing processes. This mechanism differs fundamentally from traditional erythropoietin signaling, as ara 290 peptide benefits occur through tissue-protective pathways rather than hematopoietic stimulation. The IRR complex, consisting of CD131 and erythropoietin receptor subunits, becomes activated only under conditions of tissue stress, inflammation, or metabolic challenge, making ara 290 peptide benefits particularly relevant for pathological conditions.
At the molecular level, ara 290 peptide benefits include activation of JAK2/STAT3 signaling pathways that promote anti-apoptotic gene expression and cellular survival. The peptide also modulates NF-κB activity, a master regulator of inflammatory responses, leading to reduced production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These anti-inflammatory ara 290 peptide benefits create an environment conducive to tissue repair and regeneration. Additionally, the peptide enhances expression of neurotrophic factors and promotes axonal regeneration, contributing to the observed improvements in nerve fiber density and neuropathic symptoms.
The tissue-protective ara 290 peptide benefits extend to vascular endothelium, where the peptide improves nitric oxide bioavailability and enhances microvascular circulation. This vascular protection proves particularly important in diabetic neuropathy, where microvascular dysfunction contributes significantly to nerve damage. Ara 290 peptide benefits also include protection against ischemia-reperfusion injury and promotion of angiogenesis in damaged tissues. The peptide’s ability to activate multiple protective pathways simultaneously explains its broad therapeutic potential across diverse pathological conditions, from neuropathy to inflammatory diseases and tissue injury.
Extensive clinical research has established ara 290 peptide benefits across multiple therapeutic applications, with particularly robust evidence in diabetic neuropathy and small fiber neuropathy. A landmark Phase II clinical trial published in Molecular Medicine demonstrated that ara 290 peptide benefits include significant improvements in hemoglobin A1c levels, with patients receiving 4mg daily showing sustained reductions in glycemic markers throughout the 56-day observation period. The study revealed that ara 290 peptide benefits extended beyond glucose control to include favorable changes in lipid profiles, with reduced cholesterol-to-HDL ratios and decreased triglyceride concentrations. These metabolic ara 290 peptide benefits occurred without changes in diabetes medications, suggesting direct effects on insulin sensitivity and metabolic function.
Neuropathic symptom improvements represent some of the most compelling ara 290 peptide benefits documented in clinical trials. Using validated assessment tools including PainDetect and the Neuropathic Pain Symptom Inventory, researchers observed significant reductions in neuropathic pain scores among patients receiving ara 290 peptide. The ara 290 peptide benefits included improvements in specific symptom categories such as tingling, thermal pain, and allodynia, with effects persisting for at least 28 days after treatment cessation. Patients reported enhanced quality of life measures, particularly in physical role functioning and vitality dimensions, indicating that ara 290 peptide benefits extend beyond pain reduction to include functional improvements.
Objective measurements of nerve regeneration provide powerful evidence for ara 290 peptide benefits on structural nerve repair. Corneal confocal microscopy studies demonstrated that ara 290 peptide treatment significantly increased corneal nerve fiber density in patients with confirmed small fiber neuropathy. Subjects with baseline nerve fiber density more than one standard deviation below normal showed mean increases of 2.6 fibers/mm² after 28 days of ara 290 peptide treatment, compared to minimal changes in placebo groups. These ara 290 peptide benefits on nerve regeneration correlated directly with improvements in neuropathic symptoms, establishing a clear relationship between structural nerve repair and symptomatic relief. The ability of ara 290 peptide to promote actual nerve fiber regrowth distinguishes it from symptomatic treatments that merely mask pain without addressing underlying pathology.
Clinical trials have established optimal dosing protocols that maximize ara 290 peptide benefits while maintaining excellent safety profiles. The standard therapeutic dose of 4mg daily, administered subcutaneously, has demonstrated consistent efficacy across multiple clinical studies investigating ara 290 peptide benefits for neuropathy and metabolic conditions. Research protocols typically begin with a titration period of 2mg daily during the first week to assess individual tolerance, then advance to the maintenance dose of 4mg daily for the remainder of the treatment cycle. This gradual approach ensures patients experience ara 290 peptide benefits without overwhelming their systems, though clinical data indicates excellent tolerability even at the full therapeutic dose from day one.
The 10ML vial format from PrymaLab provides flexibility for various reconstitution concentrations to suit different research protocols. A common approach involves reconstituting the entire 10ML vial with 2.5mL of bacteriostatic water, creating a 4mg/mL concentration that simplifies daily dosing. At this concentration, the 4mg therapeutic dose requires exactly 1mL injection volume, easily measured with standard insulin syringes. This reconstitution strategy ensures ara 290 peptide benefits remain consistent throughout the treatment cycle while minimizing measurement errors. Alternative concentrations can be prepared based on specific research requirements, with higher concentrations reducing injection volumes and lower concentrations providing more precise dose adjustments.
Treatment duration significantly influences the magnitude of ara 290 peptide benefits observed in clinical outcomes. Standard protocols employ 28-day treatment cycles, the duration used in pivotal clinical trials demonstrating improvements in neuropathic symptoms and nerve fiber density. However, research suggests that ara 290 peptide benefits may continue accumulating with extended treatment, with some protocols investigating 8 to 16-week cycles for chronic neuropathic conditions. The peptide’s excellent safety profile supports longer treatment durations when clinically indicated. Researchers should consider that ara 290 peptide benefits on nerve regeneration require time to manifest, as structural nerve repair occurs gradually over weeks rather than days.
Proper reconstitution techniques preserve ara 290 peptide benefits by maintaining peptide integrity and preventing degradation. Begin by allowing the lyophilized ara 290 peptide vial and bacteriostatic water to reach room temperature, as temperature differentials can cause condensation that dilutes the final concentration. Draw the calculated volume of bacteriostatic water into a sterile syringe, typically 2.5mL for a 4mg/mL concentration from a 10ML vial. Insert the needle through the rubber stopper at a slight angle, directing the water stream against the inside wall of the vial rather than directly onto the lyophilized peptide cake. This gentle technique prevents foaming and mechanical stress that could compromise ara 290 peptide benefits.
After adding bacteriostatic water, allow the vial to sit undisturbed for several minutes while the peptide dissolves naturally. Avoid vigorous shaking or agitation, as these actions can denature the delicate peptide structure and reduce ara 290 peptide benefits. Instead, gently roll the vial between your palms if needed to encourage complete dissolution. The reconstituted solution should appear clear and free of particulates or cloudiness. Any discoloration, precipitation, or visible particles indicate compromised peptide quality that may diminish ara 290 peptide benefits. Once fully reconstituted, label the vial with the reconstitution date and concentration, then immediately refrigerate at 2-8°C (36-46°F) to maintain stability.
Storage conditions critically impact ara 290 peptide benefits throughout the treatment cycle. Reconstituted ara 290 peptide maintains stability for up to 28 days when refrigerated properly, aligning perfectly with standard clinical trial protocols. Protect the vial from light exposure by storing it in its original carton or wrapping it in aluminum foil. Never freeze reconstituted ara 290 peptide, as ice crystal formation can irreversibly damage the peptide structure and eliminate therapeutic benefits. Before each injection, inspect the solution for any changes in appearance. Maintain strict aseptic technique during all withdrawals to prevent bacterial contamination that could compromise both safety and ara 290 peptide benefits.
Subcutaneous injection technique significantly influences the consistency of ara 290 peptide benefits by ensuring reliable absorption and minimizing local tissue reactions. Select injection sites with adequate subcutaneous fat, typically the lower abdomen (at least 2 inches from the navel), outer thighs, or back of upper arms. Clean the injection site thoroughly with an alcohol swab and allow it to dry completely before proceeding. Pinch a fold of skin between your thumb and forefinger, creating a raised area of subcutaneous tissue. Insert the needle at a 45 to 90-degree angle depending on the amount of subcutaneous fat present, with leaner individuals requiring a 45-degree angle to avoid intramuscular injection.
Inject ara 290 peptide slowly and steadily, taking 5-10 seconds to deliver the full dose. This gradual injection technique reduces discomfort and promotes even distribution of the peptide in subcutaneous tissue, optimizing ara 290 peptide benefits through consistent absorption. After injecting the full dose, wait a few seconds before withdrawing the needle to prevent backflow of the solution. Release the skin fold and withdraw the needle smoothly, then apply gentle pressure with a clean gauze pad. Avoid rubbing the injection site, as this can cause local irritation and potentially affect ara 290 peptide benefits through altered absorption patterns.
Systematic site rotation prevents lipohypertrophy and local tissue changes that could compromise ara 290 peptide benefits over extended treatment cycles. Divide your injection sites into zones and rotate through them in a consistent pattern, avoiding the same exact spot for at least one week. Document each injection site in a treatment log to maintain proper rotation and identify any sites that develop persistent reactions. Some individuals may experience mild redness or transient discomfort at injection sites, but these reactions typically resolve within hours and do not indicate compromised ara 290 peptide benefits. Persistent or worsening injection site reactions warrant consultation with healthcare providers to ensure optimal treatment outcomes.
Ara 290 peptide benefits for diabetic neuropathy represent one of the most extensively studied therapeutic applications, with clinical trials demonstrating improvements across multiple disease parameters. Diabetic peripheral neuropathy affects up to 50% of individuals with diabetes, causing debilitating pain, sensory loss, and functional impairment. Traditional treatments focus primarily on symptomatic pain relief without addressing the underlying nerve damage. In contrast, ara 290 peptide benefits include both symptomatic improvement and structural nerve repair, offering a disease-modifying approach to diabetic neuropathy management. Clinical data shows that ara 290 peptide treatment reduces neuropathic pain scores by approximately 18-23% from baseline, with effects persisting for weeks after treatment cessation.
The metabolic ara 290 peptide benefits extend beyond neuropathy to include improvements in glycemic control and lipid metabolism. Patients with type 2 diabetes receiving 4mg daily ara 290 peptide showed significant reductions in hemoglobin A1c levels, with mean decreases of 0.16% at day 28 and 0.21% at day 56 compared to baseline. These improvements occurred despite patients maintaining stable diabetes medications throughout the study period, suggesting direct effects of ara 290 peptide on insulin sensitivity or pancreatic beta cell function. The magnitude of A1c reduction correlated with baseline values, indicating that ara 290 peptide benefits may be most pronounced in patients with suboptimal glycemic control.
Lipid profile improvements represent additional metabolic ara 290 peptide benefits relevant to cardiovascular risk reduction in diabetic populations. Clinical trials documented significant reductions in the cholesterol-to-HDL ratio, driven by both decreased total cholesterol and increased HDL cholesterol levels. Triglyceride concentrations also improved significantly in the ara 290 peptide treatment group, with changes inversely related to baseline levels. These favorable lipid changes occurred without modifications to lipid-lowering medications, suggesting direct effects of ara 290 peptide on lipid metabolism. The combination of improved glycemic control, enhanced lipid profiles, and reduced neuropathic symptoms positions ara 290 peptide as a comprehensive therapeutic approach for diabetes complications.
The nerve regeneration ara 290 peptide benefits distinguish this therapeutic from conventional neuropathy treatments that merely provide symptomatic relief. Corneal confocal microscopy, a validated technique for quantifying small nerve fiber density, provides objective evidence of ara 290 peptide benefits on nerve structure. Clinical studies demonstrate that patients with reduced corneal nerve fiber density at baseline experience significant increases in nerve fiber counts after 28 days of ara 290 peptide treatment. The mean increase of 2.6 fibers/mm² represents substantial nerve regeneration, comparable to improvements seen after pancreas-kidney transplantation in diabetic patients. This structural nerve repair correlates directly with symptomatic improvements, establishing ara 290 peptide benefits on both objective and subjective outcome measures.
The neuroprotective ara 290 peptide benefits operate through multiple complementary mechanisms that prevent ongoing nerve damage while promoting repair of existing injury. Ara 290 peptide reduces oxidative stress in neurons, a primary driver of diabetic nerve damage, by enhancing antioxidant enzyme expression and reducing reactive oxygen species production. The peptide also prevents neuronal apoptosis through activation of survival signaling pathways including PI3K/Akt and ERK1/2. These anti-apoptotic ara 290 peptide benefits ensure that existing neurons survive despite the hostile metabolic environment of diabetes. Additionally, ara 290 peptide enhances expression of nerve growth factor and other neurotrophic factors that promote axonal sprouting and remyelination.
Microvascular improvements contribute significantly to the neuroprotective ara 290 peptide benefits observed in diabetic neuropathy. Peripheral nerve damage in diabetes results partly from microvascular dysfunction that reduces blood flow and oxygen delivery to nerves. Ara 290 peptide improves endothelial function and enhances microvascular circulation in peripheral tissues, addressing this vascular component of neuropathy. The peptide promotes angiogenesis and protects against ischemia-reperfusion injury, ensuring adequate perfusion of regenerating nerve fibers. These vascular ara 290 peptide benefits complement the direct neuroprotective effects, creating optimal conditions for nerve repair and regeneration.
The anti-inflammatory ara 290 peptide benefits provide therapeutic value across numerous conditions characterized by excessive or chronic inflammation. Ara 290 peptide potently suppresses production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, key mediators of tissue damage in inflammatory diseases. This cytokine suppression occurs through modulation of NF-κB signaling, a master regulator of inflammatory gene expression. By reducing NF-κB activation, ara 290 peptide benefits include decreased transcription of multiple inflammatory genes simultaneously. The peptide also enhances production of anti-inflammatory mediators such as IL-10, shifting the overall inflammatory balance toward resolution and repair.
Neuroinflammation represents a critical target for ara 290 peptide benefits in neuropathic pain conditions. Chronic pain states involve activation of spinal cord microglia and astrocytes that release inflammatory mediators sensitizing pain pathways. Ara 290 peptide treatment reduces microglial activation and suppresses release of pain-promoting substances in the spinal cord. These central anti-inflammatory ara 290 peptide benefits complement peripheral nerve repair, addressing pain through multiple mechanisms. Clinical trials in sarcoidosis-associated neuropathy demonstrated that ara 290 peptide reduces pain scores by approximately 40% while simultaneously increasing nerve fiber density, illustrating the dual benefits of inflammation reduction and tissue repair.
Tissue protection represents a fundamental ara 290 peptide benefit applicable to diverse organ systems beyond the nervous system. Preclinical studies demonstrate ara 290 peptide benefits in protecting heart tissue from ischemia-reperfusion injury, reducing organ damage in hemorrhagic shock, accelerating wound healing in burns, and protecting kidneys from acute injury. These broad tissue-protective effects stem from ara 290 peptide’s ability to activate innate repair mechanisms present in multiple cell types. The peptide enhances cellular stress resistance, promotes adaptive responses to injury, and accelerates tissue repair processes. While clinical development has focused primarily on neuropathy applications, the extensive preclinical evidence suggests ara 290 peptide benefits may extend to numerous other conditions characterized by tissue injury and inflammation.
The safety profile of ara 290 peptide represents a significant advantage over traditional erythropoietin therapy, with clinical trials consistently demonstrating excellent tolerability and minimal adverse events. Unlike erythropoietin, which stimulates red blood cell production and carries risks of thrombosis, hypertension, and cardiovascular complications, ara 290 peptide benefits include tissue protection without hematopoietic effects. Clinical studies monitoring hematological parameters throughout treatment found no changes in red blood cell counts, hemoglobin levels, or hematocrit values with ara 290 peptide administration. This absence of erythropoietic activity eliminates the cardiovascular safety concerns that have limited clinical use of erythropoietin for tissue-protective applications.
Adverse event profiles from clinical trials reveal that ara 290 peptide benefits come with minimal side effects. The most commonly reported adverse events include mild injection site reactions such as transient redness, slight swelling, or minor discomfort, occurring in less than 5% of patients. These local reactions typically resolve within hours without intervention and do not compromise ara 290 peptide benefits or require treatment discontinuation. Systemic adverse events prove even rarer, with occasional reports of mild headache or transient fatigue in less than 2% of patients. Importantly, the frequency and severity of adverse events in ara 290 peptide treatment groups closely match those in placebo groups, indicating that most reported events likely represent background occurrences rather than drug-related effects.
Long-term safety data supporting ara 290 peptide benefits continues accumulating through extended clinical trials and follow-up studies. Patients receiving ara 290 peptide for up to 16 weeks show no evidence of cumulative toxicity or emerging safety signals. Laboratory monitoring including comprehensive metabolic panels, liver function tests, and kidney function markers remain stable throughout extended treatment periods. No immunogenic responses or antibody formation against ara 290 peptide have been detected in clinical studies, despite repeated daily injections over weeks. This absence of immunogenicity ensures that ara 290 peptide benefits remain consistent throughout treatment without diminution from immune responses. The excellent long-term safety profile supports use of ara 290 peptide for chronic conditions requiring extended treatment durations.
While ara 290 peptide benefits include an excellent safety profile, certain contraindications and precautions warrant consideration to ensure appropriate use. Individuals with known hypersensitivity to ara 290 peptide or any formulation components should avoid this therapeutic. Although rare, allergic reactions could potentially compromise both safety and ara 290 peptide benefits. Patients with active malignancies represent a theoretical concern due to ara 290 peptide’s tissue-protective effects, which could potentially support tumor cell survival. While no clinical evidence suggests ara 290 peptide promotes cancer growth, prudent practice dictates avoiding use in patients with active malignancy until more definitive safety data becomes available.
Pregnancy and breastfeeding represent additional situations requiring caution with ara 290 peptide use. Insufficient safety data exists regarding ara 290 peptide benefits and risks during pregnancy or lactation. Animal reproductive toxicity studies have not been completed, and no clinical trials have enrolled pregnant women. The potential for ara 290 peptide to cross the placenta or enter breast milk remains unknown. Until comprehensive reproductive safety data becomes available, healthcare providers should carefully weigh potential ara 290 peptide benefits against theoretical risks when considering use in pregnant or nursing women. Alternative therapeutic approaches may prove more appropriate for these populations.
Patients with severe cardiovascular disease require individualized assessment before initiating ara 290 peptide treatment. While ara 290 peptide benefits do not include erythropoietic effects that could worsen cardiovascular conditions, the peptide’s effects on vascular function and tissue protection warrant medical supervision in patients with significant cardiac disease. Healthcare providers should monitor cardiovascular status throughout treatment to ensure ara 290 peptide benefits occur without adverse cardiovascular effects. Similarly, patients with severe renal or hepatic impairment may require dose adjustments or enhanced monitoring, though clinical trials have not identified specific concerns in these populations. The excellent overall safety profile suggests ara 290 peptide benefits can be realized safely in most patient populations with appropriate medical oversight.
The ara 290 peptide benefits occur through mechanisms distinct from most conventional therapeutics, resulting in minimal potential for drug interactions. Clinical trials have enrolled patients taking diverse medications including diabetes treatments, pain medications, cardiovascular drugs, and lipid-lowering agents without identifying significant interactions. Ara 290 peptide does not undergo metabolism through cytochrome P450 enzymes, eliminating concerns about interactions with drugs metabolized through these pathways. The peptide’s renal elimination and lack of protein binding further reduce interaction potential. These pharmacokinetic characteristics ensure that ara 290 peptide benefits remain consistent regardless of concomitant medications.
Monitoring requirements for ara 290 peptide treatment remain minimal due to the excellent safety profile and absence of significant adverse effects. Baseline assessment should include comprehensive metabolic panel, complete blood count, and evaluation of neuropathic symptoms using validated instruments. For patients with diabetes, baseline hemoglobin A1c and lipid profiles provide useful comparators for assessing metabolic ara 290 peptide benefits. During treatment, periodic monitoring of these parameters helps document therapeutic responses and ensures ara 290 peptide benefits occur as expected. However, intensive laboratory monitoring proves unnecessary given the absence of hematological, hepatic, or renal toxicity in clinical trials.
Injection site assessment represents the primary monitoring focus during ara 290 peptide treatment. Healthcare providers should instruct patients to inspect injection sites for persistent redness, swelling, or signs of infection. While mild transient reactions occur occasionally without compromising ara 290 peptide benefits, persistent or worsening local reactions warrant evaluation. Patients should also report any unexpected systemic symptoms, though clinical experience suggests such events rarely occur. The minimal monitoring requirements and excellent tolerability of ara 290 peptide support its use in diverse clinical settings, from specialized research centers to community practice environments where intensive monitoring may prove impractical.
Proper storage of lyophilized ara 290 peptide ensures maximum ara 290 peptide benefits by preserving peptide integrity and potency throughout the product shelf life. Unopened vials should be stored in a refrigerator at 2-8°C (36-46°F), the optimal temperature range for maintaining peptide stability. At these temperatures, lyophilized ara 290 peptide remains stable for up to 24 months from the manufacturing date, as confirmed through accelerated stability testing. For extended storage beyond two years, freezing at -20°C (-4°F) provides additional protection, with stability data supporting storage for up to 36 months under frozen conditions. These storage requirements ensure that ara 290 peptide benefits remain fully available when the product is reconstituted for use.
Temperature excursions during shipping or storage can potentially compromise ara 290 peptide benefits by accelerating degradation processes. Lyophilized peptides prove relatively resilient to brief temperature variations, but prolonged exposure to elevated temperatures should be avoided. If ara 290 peptide vials experience temperature excursions above 25°C (77°F) for extended periods, peptide degradation may occur, reducing therapeutic efficacy. Conversely, accidental freezing of refrigerated lyophilized vials does not harm the peptide, as the lyophilized form tolerates freezing without structural damage. Upon receipt of ara 290 peptide shipments, immediately transfer vials to appropriate storage conditions and inspect packaging for any signs of temperature abuse during transit.
Light protection represents another critical factor in preserving ara 290 peptide benefits during storage. While lyophilized peptides show greater light stability than reconstituted solutions, prolonged light exposure can still cause oxidative damage and peptide degradation. Store ara 290 peptide vials in their original cartons or in dark storage areas to minimize light exposure. Avoid storing vials in locations with direct sunlight or intense artificial lighting. These simple precautions ensure that ara 290 peptide benefits remain intact from manufacturing through reconstitution. Before reconstituting any vial, inspect the lyophilized cake for any discoloration or changes in appearance that might indicate degradation, though such changes rarely occur with proper storage.
Once reconstituted with bacteriostatic water, ara 290 peptide requires refrigerated storage to maintain stability and preserve therapeutic benefits. Store reconstituted vials at 2-8°C (36-46°F) immediately after preparation and maintain this temperature throughout the usage period. At refrigerated temperatures, reconstituted ara 290 peptide maintains stability for up to 28 days, aligning perfectly with standard clinical trial protocols. This 28-day stability window ensures that ara 290 peptide benefits remain consistent throughout typical treatment cycles without requiring frequent reconstitution. The bacteriostatic water used for reconstitution contains 0.9% benzyl alcohol preservative that inhibits bacterial growth, supporting the extended multi-dose usage period.
Never freeze reconstituted ara 290 peptide solution, as freezing causes irreversible damage to the peptide structure that eliminates therapeutic benefits. Ice crystal formation during freezing can disrupt peptide conformation and cause aggregation, rendering the solution ineffective. If reconstituted ara 290 peptide accidentally freezes, discard the vial and prepare a fresh solution to ensure full ara 290 peptide benefits. Similarly, avoid exposing reconstituted solutions to elevated temperatures above 25°C (77°F) for extended periods. Brief temperature excursions during transport from refrigerator to injection site prove acceptable, but reconstituted vials should not be left at room temperature for more than a few hours.
Light protection becomes even more critical for reconstituted ara 290 peptide compared to lyophilized form. Peptides in solution show increased susceptibility to photodegradation, with light exposure potentially causing oxidative damage and loss of potency. Store reconstituted vials in their original cartons or wrap them in aluminum foil to provide light protection. Before each use, inspect the solution for any changes in appearance including discoloration, cloudiness, or particulate matter. Clear, colorless solution indicates proper stability and full ara 290 peptide benefits. Any visible changes suggest degradation or contamination, warranting disposal of the vial and preparation of fresh solution to ensure optimal therapeutic outcomes.
Aseptic technique during all handling procedures proves essential for maintaining ara 290 peptide benefits and preventing bacterial contamination. Before accessing any vial, thoroughly wash hands and consider wearing clean gloves for additional protection. Clean the rubber stopper with an alcohol swab and allow it to dry completely before inserting a needle. This simple step removes surface contaminants that could be introduced into the vial during needle penetration. Use only sterile syringes and needles for all withdrawals, never reusing injection supplies. These basic aseptic practices ensure that ara 290 peptide benefits remain uncompromised by bacterial contamination throughout the multi-dose usage period.
The number of vial accesses influences contamination risk and potentially affects ara 290 peptide benefits over extended usage. While bacteriostatic water provides antimicrobial protection, minimizing unnecessary vial entries reduces contamination opportunities. Plan withdrawals efficiently to avoid excessive vial access. If multiple doses will be administered on the same day, consider drawing all doses simultaneously into separate syringes rather than accessing the vial multiple times. However, pre-filled syringes should be used within hours of preparation, as ara 290 peptide stability in syringes has not been extensively studied. The multi-dose vial design with bacteriostatic water provides the most reliable approach for maintaining ara 290 peptide benefits throughout the treatment cycle.
Documentation of reconstitution dates and usage tracking helps ensure ara 290 peptide benefits remain optimal throughout treatment. Label each vial clearly with the reconstitution date and discard any solution remaining after 28 days, even if it appears normal. Maintain a usage log recording each withdrawal date and volume to track remaining doses and plan timely vial replacement. This systematic approach prevents inadvertent use of expired solutions that might provide diminished ara 290 peptide benefits. Additionally, documentation supports troubleshooting if unexpected results occur, allowing correlation of outcomes with specific vial lot numbers and storage conditions. These organizational practices optimize both safety and therapeutic efficacy of ara 290 peptide treatment.
What are the main ara 290 peptide benefits?
The primary ara 290 peptide benefits include neuroprotection, nerve regeneration, anti-inflammatory effects, and tissue protection. Clinical trials demonstrate that ara 290 peptide improves neuropathic symptoms, increases nerve fiber density, enhances metabolic control in diabetes, and improves lipid profiles. Unlike erythropoietin, ara 290 peptide benefits occur without stimulating red blood cell production, eliminating cardiovascular risks. The peptide activates the innate repair receptor to promote tissue healing and reduce inflammation across multiple organ systems.
How does ara 290 differ from erythropoietin?
Ara 290 peptide benefits derive from selective activation of the innate repair receptor (IRR) without binding to the classical erythropoietin receptor that stimulates red blood cell production. This selectivity means ara 290 peptide provides all the tissue-protective benefits of erythropoietin without the serious side effects of increased hematocrit, thrombosis risk, and cardiovascular complications. Ara 290 represents an 11-amino acid peptide engineered from erythropoietin’s structure specifically to retain tissue protection while eliminating hematopoietic activity.
Is ara 290 peptide safe for long-term use?
Clinical trials demonstrate excellent safety for ara 290 peptide with treatment durations up to 16 weeks. The ara 290 peptide benefits include minimal adverse events, with only occasional mild injection site reactions reported. No hematological, hepatic, or renal toxicity has been observed. No immunogenic responses or antibody formation occurs despite repeated daily injections. The excellent long-term safety profile supports extended treatment for chronic conditions, though patients should receive appropriate medical supervision throughout therapy.
What conditions can benefit from ara 290 peptide?
The most extensively studied ara 290 peptide benefits occur in diabetic neuropathy and small fiber neuropathy, with clinical trials demonstrating significant improvements in neuropathic symptoms and nerve fiber density. Additional research suggests ara 290 peptide benefits may extend to sarcoidosis-associated neuropathy, chronic neuropathic pain, inflammatory conditions, and tissue injury. Preclinical studies show protective effects in cardiovascular disease, kidney injury, burns, and traumatic brain injury, though clinical development focuses primarily on neuropathy applications.
Where can I buy ara 290 peptide?
PrymaLab offers pharmaceutical-grade ara 290 peptide in 10ML vials suitable for research applications. Our ara 290 peptide meets stringent quality standards with complete testing documentation and lot-specific Certificates of Analysis. Purchase ara 290 peptide directly from PrymaLab to ensure authentic product with proper storage and handling throughout the supply chain. We provide temperature-controlled shipping to maintain ara 290 peptide benefits during transit, along with comprehensive product information and technical support.
What is the recommended ara 290 dosage?
Clinical trials establish 4mg daily as the optimal dose for ara 290 peptide benefits in neuropathy and metabolic applications. Treatment typically begins with 2mg daily during week one to assess tolerance, then advances to 4mg daily maintenance dose. Higher doses of 8mg daily have been studied but show no additional benefits compared to 4mg. The 4mg dose provides maximal ara 290 peptide benefits with excellent safety and tolerability. Subcutaneous injection once daily represents the standard administration route.
How do I reconstitute ara 290 peptide?
Reconstitute ara 290 peptide by adding 2.5mL bacteriostatic water to the 10ML vial, creating a 4mg/mL concentration. Draw bacteriostatic water into a sterile syringe and inject slowly down the vial wall to avoid foaming. Allow the vial to sit undisturbed for several minutes, then gently roll to ensure complete dissolution. Never shake vigorously, as this can damage the peptide structure and reduce ara 290 peptide benefits. Label with reconstitution date and refrigerate immediately at 2-8°C.
How long should I use ara 290 peptide?
Standard clinical protocols employ 28-day treatment cycles, the duration demonstrating significant ara 290 peptide benefits in pivotal trials. However, research suggests benefits may continue accumulating with extended treatment, with some protocols investigating 8 to 16-week cycles for chronic neuropathy. The excellent safety profile supports longer treatment when clinically indicated. Ara 290 peptide benefits on nerve regeneration require time to manifest, as structural repair occurs gradually. Consult healthcare providers to determine optimal treatment duration for specific conditions.
Can I mix ara 290 with other peptides?
No, never mix ara 290 peptide with other peptides in the same vial. Each peptide should be reconstituted separately to prevent chemical interactions, maintain accurate dosing, and preserve stability. Different peptides have varying optimal pH ranges, storage requirements, and stability profiles that may be incompatible. Use separate syringes for each peptide to avoid cross-contamination. If research protocols require multiple peptides, reconstitute each individually and administer them separately to ensure full ara 290 peptide benefits.
What injection sites work best for ara 290?
Optimal injection sites for ara 290 peptide include the lower abdomen (at least 2 inches from navel), outer thighs, and back of upper arms. These areas provide adequate subcutaneous fat for proper absorption and ara 290 peptide benefits. Rotate injection sites systematically to prevent lipohypertrophy and local tissue changes. Avoid areas with scars, bruises, or skin abnormalities. Clean each site with alcohol swab before injection. Proper site selection and rotation ensure consistent ara 290 peptide benefits throughout treatment.
How should I store ara 290 peptide?
Store unopened lyophilized ara 290 peptide vials refrigerated at 2-8°C (36-46°F) for up to 24 months, or frozen at -20°C (-4°F) for up to 36 months. Once reconstituted, refrigerate at 2-8°C and use within 28 days. Never freeze reconstituted solution. Protect from light by storing in original carton or wrapping in foil. Allow vials to reach room temperature before opening to prevent condensation. Proper storage ensures full ara 290 peptide benefits throughout the product shelf life.
What are the side effects of ara 290?
Ara 290 peptide benefits come with minimal side effects. The most common adverse events include mild injection site reactions (redness, slight swelling, minor discomfort) in less than 5% of patients, typically resolving within hours. Occasional mild headache or transient fatigue occurs in less than 2% of patients. No hematological, cardiovascular, hepatic, or renal toxicity has been observed. The excellent safety profile means most patients experience ara 290 peptide benefits without significant adverse effects.
Does ara 290 require refrigeration after opening?
Yes, reconstituted ara 290 peptide requires continuous refrigeration at 2-8°C (36-46°F) to maintain stability and preserve therapeutic benefits. The solution remains stable for 28 days under refrigerated conditions. Brief temperature excursions during transport from refrigerator to injection site prove acceptable, but avoid leaving reconstituted vials at room temperature for extended periods. Never freeze reconstituted solution. Proper refrigeration ensures consistent ara 290 peptide benefits throughout the multi-dose usage period.
Can ara 290 be used during pregnancy?
Insufficient safety data exists regarding ara 290 peptide use during pregnancy or breastfeeding. No clinical trials have enrolled pregnant women, and animal reproductive toxicity studies remain incomplete. The potential for ara 290 peptide to cross the placenta or enter breast milk is unknown. Until comprehensive reproductive safety data becomes available, healthcare providers should carefully weigh potential ara 290 peptide benefits against theoretical risks. Alternative therapeutic approaches may prove more appropriate for pregnant or nursing women.
What happens if ara 290 freezes?
If lyophilized ara 290 peptide accidentally freezes, no harm occurs as the lyophilized form tolerates freezing. However, if reconstituted ara 290 peptide freezes, discard the vial immediately. Freezing reconstituted solution causes ice crystal formation that irreversibly damages peptide structure, eliminating therapeutic benefits. The solution cannot be salvaged after freezing. Prepare fresh reconstituted solution to ensure full ara 290 peptide benefits. Protect reconstituted vials from freezing by storing in refrigerator compartments rather than freezer sections.
Product Name: Ara-290 (Cibinetide)
Brand: PrymaLab
Volume: 10ML per vial
Peptide Content: 10mg total per vial
Sequence: 11 amino acids derived from EPO helix B domain
Molecular Weight: 1,257 Daltons
Molecular Formula: C₅₉H₉₅N₁₇O₂₂
Purity: ≥98% by HPLC
Appearance: White to off-white lyophilized powder
Solubility: Soluble in bacteriostatic water
pH (reconstituted): 6.0-7.5
Endotoxin Level: <1.0 EU/mg
Primary Container: Type I Borosilicate Glass Vial
Closure System: Pharmaceutical-grade Rubber Stopper
Seal: Aluminum Crimp with Flip-off Cap
Labeling: Lot number, expiration date, storage conditions
Package Insert: Complete usage and safety information
Secondary Packaging: Protective carton with product information
Temperature Indicator: Included for shipping verification
Lyophilized Storage: 2-8°C (36-46°F) for 24 months; -20°C (-4°F) for 36 months
Reconstituted Storage: 2-8°C (36-46°F) for 28 days maximum
Light Protection: Store in original carton until use
Freezing (reconstituted): Do not freeze
Transportation: Maintain 2-8°C (36-46°F) during shipping
Handling: Aseptic technique required for all manipulations
Purity Testing: HPLC, Mass Spectrometry
Identity Confirmation: Amino acid analysis, peptide sequencing
Sterility Testing: USP <71> compliant
Endotoxin Testing: LAL assay, <1.0 EU/mg
Moisture Content: <5% by Karl Fischer
pH Testing: 6.0-7.5 (reconstituted solution)
Appearance: Visual inspection for color, clarity, particulates
Certificate of Analysis: Provided with each lot
BPC-157 5mg
Healing peptide with complementary tissue repair mechanisms. BPC-157 promotes angiogenesis and accelerates wound healing, working synergistically with ara 290 peptide benefits for comprehensive tissue protection. Both peptides activate repair pathways and reduce inflammation.
TB-500 5mg
Thymosin beta-4 derivative supporting tissue regeneration and repair. TB-500 enhances cell migration and differentiation, complementing ara 290 peptide benefits on nerve regeneration. Combined protocols may provide additive effects for neuroprotection and tissue healing.
Bacteriostatic Water 10ML
Pharmaceutical-grade reconstitution solution containing 0.9% benzyl alcohol preservative. Essential for proper ara 290 peptide reconstitution to ensure full therapeutic benefits. Multi-dose capability supports 28-day treatment protocols.
Insulin Syringes 1mL (100 pack)
Precision syringes with 100 unit markings for accurate ara 290 peptide dosing. 29-31 gauge needles minimize injection discomfort. Sterile, single-use design ensures safety and maintains ara 290 peptide benefits.
Alcohol Prep Pads (200 pack)
Sterile 70% isopropyl alcohol pads for injection site preparation. Essential for maintaining aseptic technique and preventing contamination. Individual packaging maintains sterility until use.
Diabetic Neuropathy Research
Ara 290 peptide benefits for diabetic neuropathy represent the most extensively validated application. Research protocols investigate effects on neuropathic pain, nerve fiber density, metabolic control, and quality of life. Standard protocols employ 4mg daily for 28 days with comprehensive outcome assessments.
Small Fiber Neuropathy Studies
Clinical research demonstrates ara 290 peptide benefits for small fiber neuropathy across multiple etiologies. Corneal confocal microscopy provides objective measurements of nerve regeneration. Protocols typically include validated symptom questionnaires and quantitative sensory testing.
Inflammatory Disease Models
Preclinical research explores ara 290 peptide benefits for various inflammatory conditions. Studies investigate effects on cytokine production, inflammatory cell activation, and tissue damage. Research protocols examine both preventive and therapeutic administration strategies.
Tissue Protection Research
Broad tissue-protective ara 290 peptide benefits support research across multiple organ systems. Studies investigate cardiovascular protection, renal injury prevention, burn healing, and traumatic brain injury. Protocols examine optimal dosing, timing, and treatment duration for different injury models.
Metabolic Syndrome Studies
Research investigates ara 290 peptide benefits for metabolic dysfunction including insulin resistance, dyslipidemia, and obesity-related complications. Studies examine effects on glucose metabolism, lipid profiles, and inflammatory markers in metabolic disease models.
PrymaLab Ara-290 10ML is intended for research use only in investigating neuroprotection, tissue repair, and anti-inflammatory mechanisms. This product is not approved for human therapeutic use and should be used only in controlled research settings by qualified investigators. Ara 290 peptide benefits described in this document reflect published scientific literature and clinical trial results. Researchers must comply with all applicable regulations governing peptide research in their jurisdictions.
This product is designated for research use only and is not intended to diagnose, treat, cure, or prevent any disease. Ara 290 peptide has been studied in clinical trials for diabetic neuropathy and small fiber neuropathy, but remains investigational without regulatory approval for therapeutic use. The ara 290 peptide benefits described represent research findings rather than approved medical indications. Researchers bear responsibility for ensuring appropriate use within their research protocols and institutional guidelines.
PrymaLab maintains comprehensive quality management systems ensuring ara 290 peptide meets pharmaceutical research standards. Each production lot undergoes extensive testing including HPLC purity analysis, mass spectrometry identity confirmation, sterility testing, and endotoxin analysis. Certificates of Analysis accompany each lot, documenting all quality control test results and confirming compliance with specifications. This documentation supports research integrity and enables traceability throughout the product lifecycle.
Researchers must follow appropriate safety protocols when handling ara 290 peptide. Use personal protective equipment including gloves and safety glasses during reconstitution and handling. Work in well-ventilated areas and avoid generating aerosols. Dispose of used vials, syringes, and needles according to institutional biohazard waste protocols. Sharps containers must be used for all needles and syringes. Follow local regulations for pharmaceutical waste disposal. These practices ensure researcher safety and environmental protection.
Ara 290 peptide benefits represent a significant advancement in neuroprotective and tissue-protective therapeutics, offering a unique mechanism through selective innate repair receptor activation. PrymaLab’s Ara-290 10ML formulation provides pharmaceutical-grade peptide suitable for comprehensive research investigating nerve regeneration, anti-inflammatory effects, and tissue protection. The extensive clinical evidence demonstrating ara 290 peptide benefits for diabetic neuropathy, combined with the excellent safety profile and absence of erythropoietic effects, positions this therapeutic as a promising approach for multiple conditions characterized by nerve damage and inflammation.
The 10ML vial format offers optimal capacity for extended research protocols while maintaining peptide stability and potency throughout treatment cycles. Whether investigating ara 290 peptide benefits for neuropathy, metabolic dysfunction, or tissue injury, researchers can rely on PrymaLab’s commitment to quality, purity, and comprehensive documentation. The ara 290 peptide benefits extend beyond symptomatic relief to include actual structural nerve repair and tissue regeneration, distinguishing this therapeutic from conventional approaches that merely mask symptoms without addressing underlying pathology.
Proper reconstitution, storage, and administration techniques maximize ara 290 peptide benefits by preserving peptide integrity and ensuring consistent therapeutic effects. Following the evidence-based protocols outlined in this document, researchers can confidently investigate ara 290 peptide applications across diverse conditions. PrymaLab stands behind every vial of ara 290 peptide with complete quality documentation, technical support, and commitment to advancing research into this innovative neuroprotective therapeutic. The future of ara 290 peptide research holds promise for expanding therapeutic applications and improving outcomes for patients suffering from neuropathy, inflammation, and tissue injury.
| Weight | 0.1 lbs |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.